Written specifically for patient education by Dr. Antonio Gargiulo, reproductive medicine and advanced reproductive surgery.

What Is Lupron, and Why Do Doctors Use It Before Fibroid Surgery?

Lupron is the brand name of a medicine called leuprolide acetate. It belongs to a group of drugs called GnRH agonists — medicines that temporarily lower the body’s estrogen level by putting the ovaries into a kind of “pause” mode. Because fibroids grow in response to estrogen, lowering estrogen causes them to shrink — usually by 30 to 50% in volume over about three months of treatment.

Doctors sometimes recommend Lupron before fibroid removal surgery (called myomectomy) for specific reasons:

– To shrink very large fibroids so they are easier to remove through small incisions

– To increase your blood count (hemoglobin) before surgery if heavy bleeding has made you anemic

– To reduce the risk of needing a blood transfusion during surgery

– To make a less invasive surgery possible when a large uterus would otherwise require a bigger incision

These are real and well-documented benefits, supported by multiple research studies and two large scientific reviews covering more than 20 clinical trials.

The Myth: “Lupron Makes Surgery Harder Because It Destroys the Tissue Planes

You may have heard — perhaps from another doctor, a friend, or something you read online — that taking Lupron before fibroid surgery makes the surgery more difficult. The specific claim goes something like this: “Lupron causes the tissue planes between the fibroid and the normal uterine muscle to become blurry or fused, making it harder for the surgeon to find the right layer and remove the fibroid cleanly.”

This is one of the most persistent myths in fibroid surgery. The scientific evidence does not support it.

Here is what the research actually shows.

What the Science Says

The tissue between a fibroid and the uterus has a name: the pseudocapsule.

Every fibroid is surrounded by a thin layer of compressed normal uterine muscle called the pseudocapsule. A good myomectomy — one that removes the fibroid completely while preserving the healthy uterus around it — is performed by finding this layer and working within it. This technique is called intracapsular myomectomy, and it is the approach used by expert fibroid surgeons.

Researchers have directly studied what Lupron does to this pseudocapsule at the tissue level. A laboratory study published in the European Journal of Obstetrics, Gynecology, and Reproductive Biology (De Falco et al., 2009) examined the pseudocapsule in women who received a GnRH agonist before surgery versus women who did not. The treated group did show some changes at the microscopic level — less active blood vessel markers in the pseudocapsule wall. However, the critical finding was this: operating time was not significantly different between the two groups. The surgeons were able to remove the fibroids just as efficiently, even though the pseudocapsule looked slightly different under a microscope. The authors proposed that the changes in the pseudocapsule actually help explain why bleeding during surgery is lower after Lupron — the tissue is less vascular. [^1]

Large scientific reviews confirm: surgery is not harder — it is often easier.

A comprehensive systematic review and meta-analysis published in PLoS ONE (de Milliano et al., 2017) analyzed 23 studies — including both laparoscopic (keyhole) and open myomectomy — and specifically looked at whether GnRH agonist pretreatment affected surgical difficulty, identification of cleavage planes, and operative outcomes. The findings:

– Blood loss during surgery was significantly reduced with GnRH agonist pretreatment — about 97 mL less for open surgery and 23 mL less for laparoscopic surgery

– Blood transfusion rates were significantly lower

– The review found no evidence that pretreatment made the surgery more difficult or that it impaired the surgeon’s ability to identify the correct tissue planes [^2]

A separate meta-analysis covering 26 randomized controlled trials (Zhang et al., 2014, Obstetrical and Gynecological Survey) reached the same conclusion: GnRH agonist pretreatment reduced fibroid and uterine volume, improved blood counts, and reduced pelvic symptoms — with no increase in surgical complications. [^3]

For laparoscopic myomectomy specifically, a meta-analysis by Chen, Motan, and Kiddoo (2011, Journal of Minimally Invasive Gynecology) reviewed randomized controlled trials and found that GnRH agonist pretreatment significantly reduced intraoperative blood loss and improved postoperative hemoglobin levels — and importantly, it did not increase operative time. If the surgery were becoming more difficult due to disrupted tissue planes, you would expect it to take longer. It does not. [^4]

A prospective study of 91 women with large fibroids (10 cm or more, or multiple fibroids 5 cm or more) published in the Journal of Minimally Invasive Gynecology (Chang et al., 2015) compared laparoscopic myomectomy with and without leuprolide acetate (Lupron) pretreatment. Women who received Lupron had shorter operating times (129 vs. 152 minutes), less blood loss (84 vs. 137 mL), lower rates of excessive bleeding (5% vs. 33%), and lower blood transfusion rates (7.5% vs. 35%). These are all signs that surgery went better, not worse. [^5]

Where Did This Myth Come From?

The confusion has two likely sources.

First, a different drug (ulipristal acetate) does appear to affect tissue planes — but it is not Lupron.

Ulipristal acetate (sold under the brand name Esmya in Europe) is a different type of medicine sometimes used to shrink fibroids. Unlike Lupron, which lowers estrogen broadly, ulipristal works directly on progesterone receptors inside the fibroid itself. Multiple studies found that ulipristal causes changes in fibroid tissue that make the surgical plane harder to find. A 2019 study by Mallick, Oxley, and Odejinmi reported that in 100% of cases where patients had received ulipristal, surgeons noted distortion of the fibroid capsule and a more technically challenging dissection — compared to 0% in untreated patients. Ulipristal is no longer widely available due to liver safety concerns, but the confusion between it and Lupron has contributed to the myth being applied to GnRH agonists like Lupron, where the evidence does not support it. [^6]

Second, there is the recurrence question — and it is real, but separate from surgical difficulty.

Some studies, including an early randomized trial by Fedele et al. (1990, British Journal of Obstetrics and Gynaecology), found that women who received GnRH agonists before surgery had a higher rate of small fibroid recurrence within 6 months after the operation. The proposed explanation: Lupron causes very small fibroids to shrink so much that they become invisible during surgery, so the surgeon cannot find and remove them — and they grow back after the estrogen level returns to normal. This is a legitimate concern, but it is about completeness of removal of small fibroids, not about difficulty with tissue planes on the main fibroid being operated on. And even this concern is context-dependent: for patients with large, symptomatic fibroids undergoing surgery to protect their uterus and improve fertility, the benefits of Lupron pretreatment for the primary fibroid consistently outweigh this risk. [^7]

A more recent development provides important context: the newest generation of GnRH medications, called antagonists (such as relugolix/Orrilissa), which work differently from Lupron, were studied in a 2025 case series and found to cause no distortion or fibrosis of the fibroid pseudocapsule, allowing complete resection in all cases. This further supports the idea that the “ruined tissue planes” claim is not a universal truth about all fibroid-shrinking medications — and specifically does not apply to Lupron when used appropriately. [^8]

The Bottom Line

Here is what the evidence shows, clearly:

– Lupron (leuprolide acetate / GnRH agonist) before fibroid surgery consistently reduces blood loss and transfusion risk.

– Multiple studies and two large meta-analyses confirm that it does **not** make surgery harder or impair the surgeon’s ability to work in the correct tissue layer.

– The “destroyed tissue planes” concern is not supported by the evidence for GnRH agonists. It is, however, a documented concern with a different drug — ulipristal acetate — which is not Lupron.

– There is a separate, real concern about small fibroids becoming temporarily invisible after Lupron, which can lead to recurrence. Your surgeon will discuss with you whether this applies to your situation.

– For the right patient — someone with large fibroids, low blood counts, or a situation where a smaller or less invasive surgery is desired — Lupron pretreatment remains a reasonable and evidence-based tool.

If you have been told that Lupron will “ruin the tissue planes” for your surgery, it is worth asking your surgeon to review the current evidence. The research does not support that claim.

Sources We Used

So You Can Read Them, Question Them, and Decide for Yourself

We believe that informed patients are empowered patients. In an age where artificial intelligence and open-access science place original research within reach of anyone, you have every right to go to the source, read it yourself, and form your own conclusions. Patient education on this website is taken seriously: we do not simplify at the cost of truth, and we do not ask you to take our word for it.

Every statement in this article carries two layers of accountability. It has been filtered through the critical eye of Dr. Antonio Gargiulo, drawing on four decades of clinical and surgical experience in reproductive medicine and advanced gynecologic surgery. And it is independently traceable to a peer-reviewed scientific publication, listed below with its full reference and digital identifier (DOI), so you can retrieve and read the original source at any time.

We see healthcare as a shared responsibility between doctors and patients. Shared responsibility requires shared access to information. These references are not a formality. They are here for you.

1. De Falco M, Staibano S, Mascolo M, et al. Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2009. DOI: 10.1016/j.ejogrb.2009.02.006

2. de Milliano I, Twisk M, Ket JC, Huirne J, Hehenkamp W. Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis. PLoS ONE. 2017. DOI: 10.1371/journal.pone.0186158

3. Zhang Y, Sun L, Guo Y, et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: A meta-analysis. Obstetrical and Gynecological Survey. 2014. DOI: 10.1097/OGX.0000000000000036

4. Chen I, Motan T, Kiddoo D. Gonadotropin-releasing hormone agonist in laparoscopic myomectomy: systematic review and meta-analysis of randomized controlled trials. *Journal of Minimally Invasive Gynecology. 2011. DOI: 10.1016/j.jmig.2011.02.010

5. Chang WC, Chu LH, Huang P, Huang SC, Sheu B. Comparison of laparoscopic myomectomy in large myomas with and without leuprolide acetate. Journal of Minimally Invasive Gynecology. 2015. DOI: 10.1016/j.jmig.2015.04.026

6. Mallick R, Oxley S, Odejinmi F. The use of ulipristal acetate (Esmya) prior to laparoscopic myomectomy: Help or hindrance? Gynecology and Minimally Invasive Therapy.* 2019. DOI: 10.4103/GMIT.GMIT_79_18

7. Fedele L, Vercellini P, Bianchi S, Brioschi D, Dorta M. Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence.British Journal of Obstetrics and Gynaecology. 1990. DOI: 10.1111/j.1471-0528.1990.tb01824.x

8. Vandermolen B, Reindorf M, McMurray R, Aref-Adib M, Odejinmi F. Preoperative relugolix combination therapy in laparoscopic myomectomy: a case series evaluating impact on surgical planes and operative outcomes. Archives of Gynecology and Obstetrics. 2025. DOI: 10.1007/s00404-025-08174-5

This document is intended for patient education. It does not replace a personal discussion with your care team about your individual situation.